Key terms
About TMDX
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TMDX news
Mar 15
10:56am ET
TransMedics participates in a conference call with JPMorgan
Feb 27
8:30am ET
TransMedics price target raised to $102 from $96 at Canaccord
Feb 27
7:48am ET
Oppenheimer Sticks to Its Buy Rating for TransMedics Group (TMDX)
Feb 27
7:38am ET
TransMedics price target raised to $105 from $92 at Oppenheimer
Feb 27
6:30am ET
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), TransMedics Group (TMDX) and MoonLake Immunotherapeutics (MLTX)
Feb 26
4:09pm ET
TransMedics sees FY24 revenue $360M-$370M, consensus $330.23M
Feb 26
4:09pm ET
TransMedics reports Q4 EPS 12, consensus (3c)
Feb 07
4:43am ET
TransMedics Expands Fleet for National OCS Program
Feb 05
4:05pm ET
Buy Rating on TransMedics Group Amidst Growing Organ Transplant Market
Jan 05
4:20am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Tecan Group AG (OtherTCHBF), TransMedics Group (TMDX) and Argenx Se (ARGX)
No recent news articles are available for TMDX
No recent press releases are available for TMDX
TMDX Financials
Key terms
Ad Feedback
TMDX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TMDX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range